Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PDGFRB A6V |
| Therapy | Regorafenib |
| Indication/Tumor Type | colorectal cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PDGFRB A6V | colorectal cancer | predicted - sensitive | Regorafenib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with metastatic colorectal cancer harboring germline PDGFRB A6V demonstrated a partial morphological and metabolic response after 8 weeks of treatment with Stivarga (regorafenib) and remained in partial remission with sustained clinical improvement for at least 9 months from the start of treatment (PMID: 25336117). | 25336117 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25336117) | A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib. | Full reference... |